2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

2:30PM-4:00PM: Abstract Number: 1796

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of Phase II of a Cluster Randomized Controlled Trial

Measures and Measurement of Healthcare Quality

2:30PM-4:00PM: Abstract Number: 1830

Bone Marrow Edema in Sacroiliac Joints of Young Athletes Is Common and Shows Most Frequently in the Posterior Lower Ilium

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II

2:30PM-4:00PM: Abstract Number: 1841

Can Systemic Lupus (SLE) Disease Activity be Consistently Scored and Interpreted with Simple, Rapid Outcome Measures?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures

2:30PM-4:00PM: Abstract Number: 1844

Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis

Vasculitis II: Biomarkers and Disease Activity

2:30PM-4:00PM: Abstract Number: 1825

Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy

2:30PM-4:00PM: Abstract Number: 1840

Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures

2:30PM-4:00PM: Abstract Number: 1827

Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II

2:30PM-4:00PM: Abstract Number: 1845

Comparison of Magnetic Resonance Angiography (MRA) and 18f-Fluorodeoxyglucose Positron Emission Tomography (PET) in Large Vessel Vasculitis

Vasculitis II: Biomarkers and Disease Activity

2:30PM-4:00PM: Abstract Number: 1805

Construct Validity of RAPID3 for Measurement of Disease Activity in Psoriatic Arthritis

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1819

Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity

Rheumatoid Arthritis – Clinical Aspects II: Treatment Patterns

2:30PM-4:00PM: Abstract Number: 1802

Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1839

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures

2:30PM-4:00PM: Abstract Number: 1818

Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study

Rheumatoid Arthritis – Clinical Aspects II: Treatment Patterns

2:30PM-4:00PM: Abstract Number: 1837

Development of Murine SLE in the Absence of BAFF

Systemic Lupus Erythematosus – Animal Models

2:30PM-4:00PM: Abstract Number: 1792

Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].